|
Pluristem to Present at
Rodman & Renshaw 5th Annual Global Healthcare Conference
Monday May 19, 10:00 am ET |
|
|
NEW YORK--(BUSINESS WIRE)--Pluristem
Therapeutics Inc. (NASDAQ:PSTI
- News)
(DAX:PJT), a bio-therapeutics company dedicated to
the commercialization of non-personalized (allogeneic)
cell therapy products for a variety of degenerative,
ischemic and autoimmune indications, today announced
that the Company will present at the Rodman &
Renshaw 5th Annual Global Healthcare Conference in
Monte Carlo, Monaco on May 20, 2008, 3:00 a.m. EDT
(9:00 a.m. Central European Summer Time). Zami
Aberman, Pluristem’s
Chairman, President and Chief Executive Officer,
will be presenting.
Mr. Zami Aberman, Pluristem's
President & CEO, stated: "We are pleased that Rodman
& Renshaw has invited us to this prestigious
conference, which will allow us to present
Pluristem's unique and innovative cellular
therapeutics business model to the investment
community. Pluristem has recently announced
pre-clinical data that demonstrates the potential of
its PLX (Placental eXpanded) cells to be
therapeutically beneficial to millions of Stroke and
MS patients, in addition to those suffering from
Peripheral Artery Disease or in need of Bone Marrow
Transplantation."
About Pluristem
Pluristem Therapeutics Inc. is a
bio-therapeutics company dedicated to the
commercialization of non-personalized (allogeneic)
cell therapy products for the treatment of several
severe degenerative, ischemic and autoimmune
disorders. The Company is developing a pipeline of
products, stored ready-to-use, that are derived from
the human placenta, a non-controversial,
non-embryonic, adult stem cell source.
These placental mesenchymal stromal
cells (MSCs) are expanded in the Company's
proprietary PluriX(TM) 3D bioreactor, which imitates
the natural microstructure of bone marrow and does
not require supplemental growth factors or other
exogenous materials. Pluristem believes that the
resultant PLX (PLacental eXpanded) cells are
multi-potent and able to differentiate into a
variety of cell types. Recent evidence also suggests
their efficacy may be related to the secretion of
cytokines or other potent immune modulators.
Furthermore, PLX cells are immune privileged and
have immunomodulatory properties, thus protecting
the recipient from immunological reactions that
often accompany transplantations.
Pluristem's first product in
development, PLX-PAD, is intended to improve the
quality of life of millions of people suffering from
peripheral artery disease (PAD). The Company's
products in development also include PLX-BMT,
targeting the global shortfall of matched tissue for
bone marrow transplantation (BMT) by improving the
engraftment of hematopoietic stem cells (HSCs)
contained in umbilical cord blood; PLX-STROKE,
targeting ischemic stroke; PLX-MS, targeting
Multiple Sclerosis; and PLX-IBD, targeting
patients suffering from Inflammatory Bowel Disease
(IBD), which includes Crohn’s
disease and Ulcerative Colitis.
Pluristem has offices in the USA
with research and manufacturing facilities in
Israel.
See our product animation on
YouTube:
http://www.youtube.com/watch?v=OFhWXyJT6Us.
Safe Harbor Statement
This press release contains
forward-looking statements within the meaning of the
"safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995 and federal securities
laws. For example, when we say that our recently
announced pre-clinical data demonstrates potential
of our PLX (Placental eXpanded) cells to be
therapeutically beneficial to millions of Stroke and
MS patients, in addition to those suffering from
Peripheral Artery Disease or in need of Bone Marrow
Transplantation, we are using forward-looking
statements. These forward-looking statements are
based on the current expectations of the management
of Pluristem only, and are subject to a number of
factors and uncertainties that could cause actual
results to differ materially from those described in
the forward-looking statements. The following
factors, among others, could cause actual results to
differ materially from those described in the
forward-looking statements: changes in technology
and market requirements; our technology may not be
validated as we progress further and our methods may
not be accepted by the scientific community; we may
be unable to retain or attract key employees whose
knowledge is essential to the development of our
products; unforeseen scientific difficulties may
develop with our process; results in the laboratory
may not translate to equally good results in real
surgical settings; our patents may not be
sufficient; our products may harm recipients;
changes in legislation; inability to timely develop
and introduce new technologies, products and
applications; loss of market share and pressure on
pricing resulting from competition, which could
cause the actual results or performance of Pluristem
to differ materially from those contemplated in such
forward-looking statements. Except as otherwise
required by law, Pluristem undertakes no obligation
to publicly release any revisions to these
forward-looking statements to reflect events or
circumstances after the date hereof or to reflect
the occurrence of unanticipated events. For a more
detailed description of the risk and uncertainties
affecting Pluristem, reference is made to
Pluristem's reports filed from time to time with the
Securities and Exchange Commission.
For more information visit our
website at
www.pluristem.com, the content of which is not
part of this press release.
Contact:
Pluristem Therapeutics Inc.
William Prather RPh, MD, 303-883-4954
Sr. VP Corporate Development
bill@pluristem.com
Source:
Pluristem Therapeutics Inc.
|
|
|
|
